Boston Scientific Investment Agreement with Exclusive Option to Acquire Farapulse, Inc.

September 21, 2020

Boston Scientific Corporation signed an investment agreement that includes an exclusive option to acquire Farapulse, Inc., a privately held developer of pulsed field ablation technology for atrial fibrillation and other cardiac arrhythmias. Farapulse’s system uses irreversible electroporation (pulsed electric fields) to ablate heart tissue without thermal energy. The platform is investigational and not available for sale.

Targets
Farapulse, Inc.
Industry
Medical Devices
Transaction Type
Addon

Explore More

Related Acquisitions

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.